Premium
Assessing Human Health Response in Life Cycle Assessment Using ED 10 s and DALYs: Part 2—Noncancer Effects
Author(s) -
Pennington David,
Crettaz Pierre,
Tauxe Annick,
Rhomberg Lorenz,
Brand Kevin,
Jolliet Olivier
Publication year - 2002
Publication title -
risk analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.972
H-Index - 130
eISSN - 1539-6924
pISSN - 0272-4332
DOI - 10.1111/1539-6924.00263
Subject(s) - extrapolation , risk assessment , econometrics , benchmark (surveying) , risk analysis (engineering) , no observed adverse effect level , point estimation , computer science , human health , environmental health , toxicology , medicine , statistics , mathematics , biology , computer security , geodesy , body weight , geography
In Part 1 of this article we developed an approach for the calculation of cancer effect measures for life cycle assessment (LCA). In this article, we propose and evaluate the method for the screening of noncancer toxicological health effects. This approach draws on the noncancer health risk assessment concept of benchmark dose, while noting important differences with regulatory applications in the objectives of an LCA study. We adopt the central tendency estimate of the toxicological effect dose inducing a 10% response over background, ED 10 , to provide a consistent point of departure for default linear low‐dose response estimates (β ED10 ). This explicit estimation of low‐dose risks, while necessary in LCA, is in marked contrast to many traditional procedures for noncancer assessments. For pragmatic reasons, mechanistic thresholds and nonlinear low‐dose response curves were not implemented in the presented framework. In essence, for the comparative needs of LCA, we propose that one initially screens alternative activities or products on the degree to which the associated chemical emissions erode their margins of exposure, which may or may not be manifested as increases in disease incidence. We illustrate the method here by deriving the β ED10 ) slope factors from bioassay data for 12 chemicals and outline some of the possibilities for extrapolation from other more readily available measures, such as the no observable adverse effect levels (NOAEL), avoiding uncertainty factors that lead to inconsistent degrees of conservatism from chemical to chemical. These extrapolations facilitated the initial calculation of slope factors for an additional 403 compounds; ranging from 10 −6 to 10 3 (risk per mg/kg‐day dose). The potential consequences of the effects are taken into account in a preliminary approach by combining the β ED10 ) with the severity measure disability adjusted life years (DALY), providing a screening‐level estimate of the potential consequences associated with exposures, integrated over time and space, to a given mass of chemical released into the environment for use in LCA.